Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
CLNN logo CLNN
Upturn stock ratingUpturn stock rating
CLNN logo

Clene Inc. (CLNN)

Upturn stock ratingUpturn stock rating
$3.6
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/14/2025: CLNN (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

6 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $27.83

1 Year Target Price $27.83

Analysts Price Target For last 52 week
$27.83 Target price
52w Low $2.28
Current$3.6
52w High $6.9

Analysis of Past Performance

Type Stock
Historic Profit -78.5%
Avg. Invested days 20
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/14/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 32.34M USD
Price to earnings Ratio -
1Y Target Price 27.83
Price to earnings Ratio -
1Y Target Price 27.83
Volume (30-day avg) 6
Beta 0.54
52 Weeks Range 2.28 - 6.90
Updated Date 08/15/2025
52 Weeks Range 2.28 - 6.90
Updated Date 08/15/2025
Dividends yield (FY) -
Basic EPS (TTM) -4.03

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -5032.1%

Management Effectiveness

Return on Assets (TTM) -49.62%
Return on Equity (TTM) -1738.36%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 43446889
Price to Sales(TTM) 92.39
Enterprise Value 43446889
Price to Sales(TTM) 92.39
Enterprise Value to Revenue 124.13
Enterprise Value to EBITDA -1.13
Shares Outstanding 8982750
Shares Floating 6140786
Shares Outstanding 8982750
Shares Floating 6140786
Percent Insiders 34.6
Percent Institutions 17.85

ai summary icon Upturn AI SWOT

Clene Inc.

stock logo

Company Overview

overview logo History and Background

Clene Inc., founded in 2012, focuses on developing bioenergetic nanocatalysis therapies for neurodegenerative diseases. It aims to improve neuronal survival and function through energy enhancement at the cellular level.

business area logo Core Business Areas

  • Neurology: Develops therapies for neurodegenerative diseases such as multiple sclerosis, Parkinson's disease, and amyotrophic lateral sclerosis (ALS).

leadership logo Leadership and Structure

Rob Etherington serves as CEO. The company has a board of directors overseeing strategic direction and corporate governance.

Top Products and Market Share

overview logo Key Offerings

  • CNM-Au8: An investigational gold nanocrystal suspension intended to enhance neuronal function. Currently undergoing clinical trials for multiple sclerosis, Parkinson's disease, and ALS. Its competitors are the other treatments for these diseases which include but are not limited to Biogen (BIIB), Teva Pharmaceuticals (TEVA), and Mitsubishi Tanabe Pharma (MTLFF).

Market Dynamics

industry overview logo Industry Overview

The neurodegenerative disease treatment market is large and growing due to an aging population. It is characterized by high unmet needs and significant R&D investment.

Positioning

Clene Inc. is a clinical-stage biotech company focused on a novel approach (nanocatalysis) within the neurodegenerative disease space. Its competitive advantage lies in its unique technology and potential for disease modification.

Total Addressable Market (TAM)

The TAM for neurodegenerative disease treatments is estimated to be in the tens of billions of dollars annually. Clene is positioned to capture a share of this market if its therapies are approved.

Upturn SWOT Analysis

Strengths

  • Novel nanocatalysis technology
  • Potential for disease modification
  • Experienced management team
  • Focus on high unmet needs

Weaknesses

  • Clinical stage company (high risk)
  • Limited financial resources
  • Dependence on clinical trial outcomes
  • Potential for regulatory hurdles

Opportunities

  • Positive clinical trial results
  • Partnerships with larger pharmaceutical companies
  • Expansion into new indications
  • Advancements in nanotechnology

Threats

  • Clinical trial failures
  • Competition from existing therapies
  • Regulatory setbacks
  • Changes in reimbursement policies

Competitors and Market Share

competitor logo Key Competitors

  • BIIB
  • TEVA
  • AMGN

Competitive Landscape

Clene Inc. faces competition from established pharmaceutical companies with approved therapies for neurodegenerative diseases. Its competitive advantage lies in its novel mechanism of action, but it faces the challenge of demonstrating clinical efficacy and safety.

Growth Trajectory and Initiatives

Historical Growth: Historical growth is characterized by progress in clinical development and securing funding.

Future Projections: Future growth is contingent on positive clinical trial outcomes and regulatory approvals for CNM-Au8. Analyst estimates vary widely.

Recent Initiatives: Recent initiatives include enrolling patients in ongoing clinical trials and exploring partnerships with other companies.

Summary

Clene Inc. is a high-risk, high-reward clinical-stage company developing a novel therapeutic approach for neurodegenerative diseases. Its success hinges on positive clinical trial results and regulatory approvals. The company faces competition from established players and the inherent risks associated with drug development. Their unique technology could address a vast market need.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Website
  • SEC Filings
  • ClinicalTrials.gov
  • Analyst Reports (Factset, etc.)

Disclaimers:

This analysis is for informational purposes only and should not be considered investment advice. The information provided is based on publicly available data and analyst estimates, which are subject to change. Investing in biotechnology companies involves significant risks, including the risk of losing your entire investment.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Clene Inc.

Exchange NASDAQ
Headquaters Salt Lake City, UT, United States
IPO Launch date 2020-12-31
CEO, President & Director Mr. Robert Etherington MBA
Sector Consumer Defensive
Industry Packaged Foods
Full time employees 75
Full time employees 75

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.